Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Carolyn Sasse"'
Autor:
Andrew Krivoshik, Anne Keating, Howard A. Ball, Chip Van Sant, Jihong Chen, Sandra Vossen, Carolyn Sasse, Ferry A.L.M. Eskens, John Bridgewater, Igor Kiss, Al B. Benson
Patient Disposition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01105bff1777c1397f541eae29d56c27
https://doi.org/10.1158/1078-0432.22465994.v1
https://doi.org/10.1158/1078-0432.22465994.v1
Autor:
Andrew Krivoshik, Anne Keating, Howard A. Ball, Chip Van Sant, Jihong Chen, Sandra Vossen, Carolyn Sasse, Ferry A.L.M. Eskens, John Bridgewater, Igor Kiss, Al B. Benson
Purpose: Tivozanib, a selective inhibitor of VEGFR-1, -2, and -3, plus mFOLFOX6 in an advanced gastrointestinal cancer phase Ib study had encouraging antineoplastic activity and a tolerable safety profile. This randomized, open-label, phase II trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bd2433571458a2c7b1177e742d38e04
https://doi.org/10.1158/1078-0432.c.6526211
https://doi.org/10.1158/1078-0432.c.6526211
Autor:
Andrew Krivoshik, Anne Keating, Howard A. Ball, Chip Van Sant, Jihong Chen, Sandra Vossen, Carolyn Sasse, Ferry A.L.M. Eskens, John Bridgewater, Igor Kiss, Al B. Benson
Baseline Patient Characteristics: Serum Biomarker Analysis Group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67acba28d794ce23e2eea8934ce3ef20
https://doi.org/10.1158/1078-0432.22465991.v1
https://doi.org/10.1158/1078-0432.22465991.v1
Autor:
Christopher J. Hoimes, Thomas W. Flaig, Matthew I. Milowsky, Terence W. Friedlander, Mehmet Asim Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R. Merchan, Rana R. McKay, Daniel P. Petrylak, Carolyn Sasse, Blanca Homet Moreno, Yao Yu, Anne-Sophie Carret, Jonathan E. Rosenberg
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 41(1)
PURPOSE Cisplatin-based combination chemotherapy remains the standard of care for locally advanced or metastatic urothelial cancer (la/mUC); however, toxicity is substantial, responses are rarely durable, and many patients with la/mUC are ineligible.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b99f57b97f76eb04a93f1f5e925cd5fd
https://pubmed.ncbi.nlm.nih.gov/36041086
https://pubmed.ncbi.nlm.nih.gov/36041086
Autor:
Christopher J. Hoimes, Thomas W. Flaig, Sandy Srinivas, Nataliya Mar, Daniel P. Petrylak, Peter H. O'Donnell, Mehmet Asim Bilen, Carolyn Sasse, Yao Yu, Matthew Birrenkott, Jonathan E. Rosenberg
Publikováno v:
Journal of Clinical Oncology. 40:TPS587-TPS587
TPS587 Background: The current standard of care for patients (pts) with newly diagnosed MIBC is neoadjuvant cisplatin (cis)-based chemotherapy followed by radical cystectomy and pelvic lymph node dissection (RC+PLND). For the 20-50% pts who are cis-i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1aefb0d2b75da00b9de48c236b0bcba6
https://doi.org/10.1200/jco.2022.40.6_suppl.tps587
https://doi.org/10.1200/jco.2022.40.6_suppl.tps587
Autor:
Carolyn Sasse, Ritesh S. Kataria, Matthew I. Milowsky, Anne-Sophie Carret, Daniel P. Petrylak, Sandy Srinivas, Terence W. Friedlander, Rana R. McKay, Thomas W. Flaig, Elizabeth Henry, Arjun Vasant Balar, Mehmet Asim Bilen, Yao Yu, Jonathan E. Rosenberg, Christopher J. Hoimes
Publikováno v:
Journal of Clinical Oncology. 39:4528-4528
4528 Background: Significant unmet need remains for people with cisplatin-ineligible (cis-ineligible) locally advanced or metastatic urothelial carcinoma (la/mUC). In the first-line (1L) setting, carboplatin-based regimens have demonstrated poor tole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::021e1e275cb3175b9fbfb92f2c04f7dc
https://doi.org/10.1200/jco.2021.39.15_suppl.4528
https://doi.org/10.1200/jco.2021.39.15_suppl.4528
Autor:
Al B. Benson, John Bridgewater, Igor Kiss, Jihong Chen, Carolyn Sasse, Sandra Vossen, Andrew Krivoshik, Ferry A.L.M. Eskens, Howard A. Ball, Anne Keating, Charles Van Sant
Publikováno v:
Clinical Cancer Research, 22(20), 5058-5067. American Association for Cancer Research Inc.
Purpose: Tivozanib, a selective inhibitor of VEGFR-1, -2, and -3, plus mFOLFOX6 in an advanced gastrointestinal cancer phase Ib study had encouraging antineoplastic activity and a tolerable safety profile. This randomized, open-label, phase II trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d95348a748c8bc3cf7c06f595f725f03
https://doi.org/10.1158/1078-0432.ccr-15-3117
https://doi.org/10.1158/1078-0432.ccr-15-3117
Autor:
Ilana Oren, Jo Anne H. Young, Ploenchan Chetchotisakd, George J Alangaden, Sameer R. Melinkeri, John R. Perfect, Sutep Jaruratanasirikul, Jörg Janne Vehreschild, Janice M. Brown, Zdeněk Ráčil, Johan Maertens, Oliver A. Cornely, Raoul Herbrecht, Masanori Ito, Peter G. Pappas, Rodrigo Ribeiro dos Santos, Souha S. Kanj, Bernhardt Zeiher, Rochelle Maher, Maria J G T Vehreschild, Luis Ostrosky-Zeichner, Francisco M. Marty, Nikolai Klimko, Galia Rahav, Stefan Schwartz, David N. Fredricks, Marc Engelhardt, Werner J. Heinz, George Richard Thompson, Kathleen M. Mullane, Carolyn Sasse, Achim Kaufhold, Galina Klyasova, Misun Lee
Publikováno v:
The Lancet Infectious Diseases. 16:828-837
Summary Background Mucormycosis is an uncommon invasive fungal disease with high mortality and few treatment options. Isavuconazole is a triazole active in vitro and in animal models against moulds of the order Mucorales. We assessed the efficacy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa40c8b211668d1d145bd7c837aa9022
https://doi.org/10.1016/s1473-3099(16)00071-2
https://doi.org/10.1016/s1473-3099(16)00071-2
Autor:
Daniel P. Petrylak, Jaime R. Merchan, Nancy Yuan, Mehmet Asim Bilen, Thomas W. Flaig, Christopher J. Hoimes, Anne-Sophie Carret, Matthew I. Milowsky, Sandy Srinivas, Jonathan E. Rosenberg, Terence W. Friedlander, Carolyn Sasse
Publikováno v:
Journal of Clinical Oncology. 38:5044-5044
5044 Background: Platinum chemotherapy is the standard for patients (pts) with metastatic urothelial carcinoma (mUC) in the first line (1L) setting. PD-1/PD-L1 inhibitors, such as pembrolizumab (P), have shown promising durability in this setting for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf1df9de5a0c5571f7f8b475a30e446c
https://doi.org/10.1200/jco.2020.38.15_suppl.5044
https://doi.org/10.1200/jco.2020.38.15_suppl.5044
Autor:
Carolyn Sasse, Daniel P. Petrylak, Thomas W. Flaig, Marya F. Chaney, Jonathan E. Rosenberg, Christopher J. Hoimes, Anne-Sophie Carret
Publikováno v:
Journal of Clinical Oncology. 38:TPS595-TPS595
TPS595 Background: Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle invasive urothelial cancer (MIUC) before radical cystectomy (RC) and lymph node dissection in cisplatin-eligible patients (pts). However, many pts are cisplati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c5cb7b0ec7c5a8e1d1c9ba5b2aa6acf
https://doi.org/10.1200/jco.2020.38.6_suppl.tps595
https://doi.org/10.1200/jco.2020.38.6_suppl.tps595